Lexaria Bioscience (LEXX) – Analysts’ Weekly Ratings Changes

A number of firms have modified their ratings and price targets on shares of Lexaria Bioscience (NASDAQ: LEXX) recently:

• 12/15/2025 – Lexaria Bioscience had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Lexaria Bioscience had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/7/2025 – Lexaria Bioscience was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 12/2/2025 – Lexaria Bioscience had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/29/2025 – Lexaria Bioscience was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 11/26/2025 – Lexaria Bioscience had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/20/2025 – Lexaria Bioscience had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 10/31/2025 – Lexaria Bioscience had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a biotech company specializing in the development and commercialization of proprietary drug delivery platforms. The company’s flagship technology, DehydraTECH, is designed to improve the oral bioavailability, onset time and overall efficiency of active molecules such as cannabinoids, nicotine and other lipophilic compounds. Lexaria’s platform seeks to address absorption challenges commonly associated with oral delivery by enhancing the rate and extent at which compounds enter the bloodstream.

Founded in 2014 and headquartered in Kelowna, British Columbia, Lexaria operates in the pharmaceutical, nutraceutical and consumer product markets.